This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Johnson & Johnson (JNJ) Stock Moves -1.48%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $131.04, moving -1.48% from the previous trading session.
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
Gilead Expands Access to Experimental Coronavirus Treatment
by Zacks Equity Research
Gilead (GILD) looks to expand access programs to accelerate access to remdesivir for COVID-19 patients.
J&J Plans to Initiate Coronavirus Vaccine Study in September
by Zacks Equity Research
J&J (JNJ) announces its plan to start an early-stage clinical study on its selected vaccine candidate in September. The company also expands agreement with BARDA to accelerate vaccine development.
Stock Market News for Mar 31, 2020
by Zacks Equity Research
Benchmarks gained on Monday, boosted by healthcare companies that are trying their best to bring the pandemic to a halt.
Should iShares Morningstar Large-Cap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
While most elective procedures are being deferred, the innovator of minimally-invasive heart valve replacement beats on
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $119.40, moving +0.18% from the previous trading session.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for IWX
AbbVie's Venclexta Combo Meets Endpoints in Leukemia Study
by Zacks Equity Research
AbbVie's (ABBV) blood cancer drug, Venclexta, in combination with azacitidine, achieves statistically significant improvement in overall survival and composite complete remission rate in treatment-naive AML patients.
Lilly Halts Enrollment, Biotechs Focus to Find Coronavirus Cure
by Kinjel Shah
Supply-chain disruptions due to coronavirus outbreak may hurt biotech companies' first-quarter earnings. However, those making treatments/vaccines may make huge profits if their products get approval.
Glaxo's Long-Acting HIV Regimen Cabenuva Gets Canada's Nod
by Kinjel Shah
Glaxo's (GSK) long-acting injectable regimen of cabotegravir and rilpivirine gets its first approval for the treatment of HIV-1 infection in virologically-suppressed adults
Is AbbVie a Good Stock to Buy Amid Coronavirus Uncertainty?
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are off to a strong start.
Lilly Gets CRL for Jardiance in Type I Diabetes Indication
by Zacks Equity Research
Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA.
Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
by Kinjel Shah
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
IMV to Develop Vaccine Candidate Against COVID-19, Shares Up
by Zacks Equity Research
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
J&J Files NDA for Multiple Sclerosis Drug Ponesimod in U.S.
by Zacks Equity Research
Johnson & Johnson's (JNJ) ponesimod's regulatory application in U.S is based on data from the head-to-head OPTIMUM phase III study, comparing it to Sanofi's MS drug, Aubagio.
My Top 10 Stock Watch List
by Daniel Laboe
Remember to wash your hands before and after each trade
Johnson & Johnson (JNJ) Stock Moves -1.19%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $134.96, moving -1.19% from the previous trading session.
Johnson & Johnson (JNJ) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
Johnson & Johnson (JNJ) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Mallinckrodt Completes NDA Submission for Kidney Failure Drug
by Zacks Equity Research
Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Calling A Bottom
by Daniel Laboe
Now is the time to start upgrading your portfolio
Coronavirus Vaccine Trial Begins, Biotech Competition Heats Up
by Kaibalya Pravo Dey
While the overall vaccine development process has been impressively fast so far, it might take 12-18 months to fully validate a potential vaccine.